PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22357877-2 2012 This was accomplished by demonstrating their ability to perform molecular targeting of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in human hepatocellular carcinoma (HCC) by using percutaneous injection of either inhibitor--3-bromopyruvate (3-BrPA) or short hairpin RNA (shRNA). bromopyruvate 246-252 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 87-127 22357877-2 2012 This was accomplished by demonstrating their ability to perform molecular targeting of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in human hepatocellular carcinoma (HCC) by using percutaneous injection of either inhibitor--3-bromopyruvate (3-BrPA) or short hairpin RNA (shRNA). bromopyruvate 246-252 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 129-134 22357885-4 2012 Tumor-specific GAPDH inhibition was achieved by using percutaneous injection of GAPDH antagonists-3-bromopyruvate (3-BrPA) or GAPDH-specific short hairpin RNA (shRNA). bromopyruvate 98-113 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 15-20 22357885-4 2012 Tumor-specific GAPDH inhibition was achieved by using percutaneous injection of GAPDH antagonists-3-bromopyruvate (3-BrPA) or GAPDH-specific short hairpin RNA (shRNA). bromopyruvate 98-113 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 80-85 22357885-4 2012 Tumor-specific GAPDH inhibition was achieved by using percutaneous injection of GAPDH antagonists-3-bromopyruvate (3-BrPA) or GAPDH-specific short hairpin RNA (shRNA). bromopyruvate 98-113 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 80-85 22357885-4 2012 Tumor-specific GAPDH inhibition was achieved by using percutaneous injection of GAPDH antagonists-3-bromopyruvate (3-BrPA) or GAPDH-specific short hairpin RNA (shRNA). bromopyruvate 115-121 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 15-20 22357885-9 2012 In vivo, percutaneous injection of GAPDH antagonists into luc-Hep3B tumors decreased bioluminescence imaging signal and viability (3-BrPA, P < .0001; GAPDH shRNA, P = .03). bromopyruvate 131-137 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 35-40 22357885-10 2012 The 3-BrPA treatment primarily inhibited GAPDH activity (74.5%) compared with its expression (34.3%), whereas GAPDH shRNA inhibited both activity (60.6%) and expression (44.4%). bromopyruvate 4-10 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 41-46 22357885-11 2012 Targeted inhibition of GAPDH by using 3-BrPA or shRNA induced apoptosis. bromopyruvate 38-44 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 23-28 20044597-0 2009 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. bromopyruvate 71-86 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 0-40 20393016-3 2010 Recently, we reported that the pyruvate analog 3-bromopyruvate (3-BrPA) promoted tumor cell death by targeting GAPDH. bromopyruvate 47-62 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 111-116 20393016-3 2010 Recently, we reported that the pyruvate analog 3-bromopyruvate (3-BrPA) promoted tumor cell death by targeting GAPDH. bromopyruvate 64-70 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 111-116 20420565-5 2010 We describe that the primary mechanism of 3-bromopyruvate is via preferential alkylation of GAPDH and that 3-bromopyruvate mediated cell death is linked to generation of free radicals. bromopyruvate 42-57 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 92-97 20044597-7 2009 CONCLUSION: GAPDH pyruvylation by 3BrPA affects its enzymatic function and is the primary intracellular target in 3BrPA mediated cancer cell death. bromopyruvate 34-39 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 12-17 20044597-7 2009 CONCLUSION: GAPDH pyruvylation by 3BrPA affects its enzymatic function and is the primary intracellular target in 3BrPA mediated cancer cell death. bromopyruvate 114-119 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 12-17 20044597-0 2009 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. bromopyruvate 71-86 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 42-47 20044597-4 2009 METHODS AND RESULTS: In the current study, using radiolabeled ((14)C) 3BrPA in multiple cancer cell lines, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was identified as the primary intracellular target of 3BrPA, based on two-dimensional (2D) gel electrophoretic autoradiography, mass spectrometry and immunoprecipitation. bromopyruvate 70-75 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 107-147 20044597-4 2009 METHODS AND RESULTS: In the current study, using radiolabeled ((14)C) 3BrPA in multiple cancer cell lines, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was identified as the primary intracellular target of 3BrPA, based on two-dimensional (2D) gel electrophoretic autoradiography, mass spectrometry and immunoprecipitation. bromopyruvate 70-75 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 149-154 20044597-4 2009 METHODS AND RESULTS: In the current study, using radiolabeled ((14)C) 3BrPA in multiple cancer cell lines, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was identified as the primary intracellular target of 3BrPA, based on two-dimensional (2D) gel electrophoretic autoradiography, mass spectrometry and immunoprecipitation. bromopyruvate 210-215 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 107-147 20044597-4 2009 METHODS AND RESULTS: In the current study, using radiolabeled ((14)C) 3BrPA in multiple cancer cell lines, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was identified as the primary intracellular target of 3BrPA, based on two-dimensional (2D) gel electrophoretic autoradiography, mass spectrometry and immunoprecipitation. bromopyruvate 210-215 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 149-154 20044597-5 2009 Furthermore, in vitro enzyme kinetic studies established that 3BrPA has marked affinity to GAPDH. bromopyruvate 62-67 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 91-96 30395437-1 2018 3-Bromopyruvate (3BP) is a potential anticancer agent viewed as a glycolytic inhibitor that preferentially kills cancer cells through inhibition of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), resulting in severe energy depletion. bromopyruvate 0-15 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 148-188 30395437-1 2018 3-Bromopyruvate (3BP) is a potential anticancer agent viewed as a glycolytic inhibitor that preferentially kills cancer cells through inhibition of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), resulting in severe energy depletion. bromopyruvate 0-15 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 190-195 28387379-5 2017 Both sperm motility and AMV decreased following treatment with iodoacetamide (IODO) and 3-bromopyruvic acid (3BP), both of which are inhibitors of glycolytic enzymes including glyceraldehyde-3-phosphate dehydrogenase (GAPDH). bromopyruvate 88-107 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 176-216 28387379-5 2017 Both sperm motility and AMV decreased following treatment with iodoacetamide (IODO) and 3-bromopyruvic acid (3BP), both of which are inhibitors of glycolytic enzymes including glyceraldehyde-3-phosphate dehydrogenase (GAPDH). bromopyruvate 88-107 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 218-223 28387379-5 2017 Both sperm motility and AMV decreased following treatment with iodoacetamide (IODO) and 3-bromopyruvic acid (3BP), both of which are inhibitors of glycolytic enzymes including glyceraldehyde-3-phosphate dehydrogenase (GAPDH). bromopyruvate 109-112 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 176-216 28387379-5 2017 Both sperm motility and AMV decreased following treatment with iodoacetamide (IODO) and 3-bromopyruvic acid (3BP), both of which are inhibitors of glycolytic enzymes including glyceraldehyde-3-phosphate dehydrogenase (GAPDH). bromopyruvate 109-112 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 218-223 25644152-11 2015 3-BrPA significantly decreased glycolytic activity, which may be due to adenosine triphosphate (ATP) depletion and decreased expression of GAPDH. bromopyruvate 0-6 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 139-144 24715475-1 2014 3-Bromopyruvic acid (3-BP) is a promising anticancer compound because it is a strong inhibitor of glycolytic enzymes, especially glyceraldehyde 3-phosphate dehydrogenase. bromopyruvate 0-19 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 129-169 24715475-1 2014 3-Bromopyruvic acid (3-BP) is a promising anticancer compound because it is a strong inhibitor of glycolytic enzymes, especially glyceraldehyde 3-phosphate dehydrogenase. bromopyruvate 21-25 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 129-169 23267123-3 2013 Biochemically, the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has been identified as the primary target of 3-bromopyruvate. bromopyruvate 131-146 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 79-84 23267123-8 2013 Taken together, the specificity of molecular (GAPDH) targeting and selective uptake by tumor cells, underscore the potential of 3-bromopyruvate as a potent and promising anticancer agent. bromopyruvate 128-143 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 46-51